Stock 002581 SHANDONG SINOBIOWAY BIOMEDICINE CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shandong Sinobioway Biomedicine Co., Ltd.

Equities

002581

CNE1000012Y5

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-06-26 EDT 		5-day change 1st Jan Change
9.87 CNY -0.20% Intraday chart for Shandong Sinobioway Biomedicine Co., Ltd. -2.08% -32.40%
04-29 Shandong Sinobioway Biomedicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-29 Shandong Sinobioway Biomedicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 4,262 4,776 12,093 14,085 10,391 9,632
Enterprise Value (EV) 1 3,917 4,569 11,976 14,075 10,372 9,495
P/E ratio -44.5 x 75.3 x -61.7 x 52 x -706 x -29 x
Yield - - - - - -
Capitalization / Revenue 6.41 x 8.41 x 43.7 x 35 x 29.1 x 22.4 x
EV / Revenue 5.89 x 8.05 x 43.3 x 34.9 x 29 x 22.1 x
EV / EBITDA 74.3 x -86 x -59.7 x -97.5 x -93.8 x -109 x
EV / FCF -6.47 x 11.4 x -1,856 x 7,692 x 121 x -88.3 x
FCF Yield -15.5% 8.8% -0.05% 0.01% 0.83% -1.13%
Price to Book 1.54 x 2.07 x 5.71 x 5.9 x 4.38 x 4.66 x
Nbr of stocks (in thousands) 659,736 659,736 659,736 659,736 659,736 659,736
Reference price 2 6.460 7.240 18.33 21.35 15.75 14.60
Announcement Date 19-04-24 20-06-23 21-04-28 22-04-29 23-04-26 24-04-29
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 664.6 567.6 276.8 402.7 357.1 429.8
EBITDA 1 52.69 -53.16 -200.7 -144.4 -110.6 -87.43
EBIT 1 -6.555 -111.2 -260.3 -203.9 -175.6 -155.8
Operating Margin -0.99% -19.58% -94.04% -50.64% -49.17% -36.25%
Earnings before Tax (EBT) 1 -83.18 76.77 -201.8 278.6 12.72 -313.2
Net income 1 -95.79 63.38 -195.9 271 -14.69 -332.5
Net margin -14.41% 11.17% -70.78% 67.29% -4.11% -77.35%
EPS 2 -0.1452 0.0961 -0.2970 0.4108 -0.0223 -0.5039
Free Cash Flow 1 -605.5 402.1 -6.454 1.83 85.69 -107.5
FCF margin -91.11% 70.84% -2.33% 0.45% 24% -25.02%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - 634.39% - 0.68% - -
Dividend per Share - - - - - -
Announcement Date 19-04-24 20-06-23 21-04-28 22-04-29 23-04-26 24-04-29
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 345 207 117 10.6 18.5 137
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -606 402 -6.45 1.83 85.7 -108
ROE (net income / shareholders' equity) -3.22% 2.8% -8.66% 12% -0.04% -13.8%
ROA (Net income/ Total Assets) -0.1% -1.8% -5.55% -4.9% -3.91% -3.74%
Assets 1 97,051 -3,522 3,528 -5,529 375.8 8,889
Book Value Per Share 2 4.190 3.500 3.210 3.620 3.600 3.140
Cash Flow per Share 2 2.340 1.700 0.4300 0.2800 0.2800 0.2300
Capex 1 608 36.3 67.7 60.8 31.5 4.32
Capex / Sales 91.52% 6.39% 24.45% 15.11% 8.81% 1%
Announcement Date 19-04-24 20-06-23 21-04-28 22-04-29 23-04-26 24-04-29
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
SHANDONG SINOBIOWAY BIOMEDICINE CO., LTD. Stock Shandong Sinobioway Biomedicine Co., Ltd.
-32.40% 898M
CSL LIMITED Stock CSL Limited
+2.97% 94.74B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-3.68% 37.28B
BIOGEN INC. Stock Biogen Inc.
-11.49% 32.68B
UCB Stock UCB
+74.21% 27.72B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-13.94% 16.19B
INCYTE CORPORATION Stock Incyte Corporation
-2.15% 13.88B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.21% 11.58B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+188.83% 10.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-53.94% 9.54B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 002581 Stock
  4. Financials Shandong Sinobioway Biomedicine Co., Ltd.